Targeting MAP4K4 could be a promising alternative mean of ERK pathway inhibition and MAP4K4 coinhibition could prevent or circumvent resistance to vertical inhibition of EGFR/RAS/RAF/MEK pathway in a broad range of patients with lung adenocarcinoma. This evidence concerns the gene MAPK1 and lung adenocarcinoma.